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Abstract
Background: This study investigated survival probabilities and prognostic factors in sentinel lymph node biopsy (SLNB)
staged patients with cutaneous melanoma (CM) with the aim of defining subgroups of patients who are at higher risk for
recurrences and who should be considered for adjuvant clinical trials.
Methods: Patients with primary CM who underwent SLNB in the Department of Dermatology, University of Tuebingen,
Germany, between 1996 and 2009 were included into this study. Survival probabilities and prognostic factors were
evaluated by Kaplan-Meier and multivariate Cox proportional hazard models.
Results: 1909 SLNB staged patients were evaluated. Median follow-up time was 44 months. Median tumor thickness was
1.8 mm, ulceration was present in 31.8% of cases. The 5-year Overall Survival (OS) was 90.3% in SLNB negative patients (IB
96.2%, IIA 87.0%, IIB 78.1%, IIC 72.6%). Patients with micrometastases (stage IIIA/B) had a 5-year OS rate of 70.9% which was
clearly less favorable than for stages I–II. Multivariate analysis revealed tumor thickness, ulceration, body site,
histopathologic subtype and SLNB status as independent significant prognostic factors.
Conclusion: Survival rates of patients with primary CM in stages I–II were shown to be much more favorable than previously
reported from non sentinel node staged collectives. For future clinical trials, sample size calculations should be adapted
using survival probabilities based on sentinel node staging.
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Introduction
Sentinel lymph node biopsy (SLNB) is a minimally invasive
procedure with minor morbidity for patients with cutaneous
melanoma (CM). SLNB allows to ascertain the status of the
regional node field and assists with exact staging [1–3]. During the
last decade SLNB has become a routinely performed procedure in
most melanoma centers worldwide [4–6] There is international
consent that SLNB should be discussed with and recommended to
patients when at least one of the following indications is present
[1]: (1) the risk of clinically occult nodal metastases is sufficient to
justify the procedure (approximately 10%); (2) the prognostic
information from SLNB would be of value to the patient and the
treating physicians; (3), the tumor status of the SLN would be
useful in guiding decisions regarding complete lymphadenectomy
and adjuvant therapy; (4) nodal staging information is important
for entry into clinical trials if the patient is interested; and/or (5)
the risks of SLNB are acceptable to the physician and the patient
[7]. SLNB is regarded to be a valuable procedure for CM patients
allowing to stage regional lymph nodes with little morbidity [5,8].
The accuracy of SLNB staging has been shown through a
long-term follow-up of SLNB negative patients. These patients
have an improved survival compared to the SLNB positive
group, and have less regional recurrences in the mapped node
fields [3]. In SLNB staged patients nodal recurrences seem to
occur less frequent but so far recurrence rates were reported in
only a few case series, some of which had limited follow-up
[4,9–14]. As the presence of nodal micrometastases is the single
most important prognostic factor [5] patients want to get this
information to be considered for new therapies under
evaluation in clinical trials, and to make an informed decision
about complete lymphadenectomy and adjuvant therapy. In
addition, the information provided by a positive SN can be used
to counsel patients regarding enrollment into clinical trials and
can serve as the basis for discussing screening and follow-up
regimen [15].
So far, few data on survival probabilities and prognostic factors
in SLNB staged patients were reported. In order to validate the
AJCC classification, Balch and Co-workers evaluated stage I/III
CM patients who were considered as clinically node negative [16].
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Table 1. Five-year overall survival (OS) and disease-free survival (DFS) probabilities based on Kaplan-Meier in sentinel node
staged patients with CM (n = 1909).
Prognostic Factor
Number of Patients
n (%)
Censored (%)
at OS
P value 5-year
OS [95% CI]
Censored (%)
at DFS
P-value 5-year DFS
[95% CI]
Thickness P,0.0001 P,0.001
#1.00 mm 188 (9.8%) 96.8 97.5 [94.6, 100] 94.1 96.9 [94.2, 99.6]
1.01–2.00 mm 934 (48.9%) 93.9 93.0 [90.7, 95.3] 86.6 84.2 [81.3, ,87.1]
2.01–4.00 mm 565 (29.6%) 86.2 82.8 [78.7, 86.9] 71.9 64.2 [59.7, 68.7]
.4 mm 222 (11.6%) 77.9 68.3 [60.1, 76.5] 61.7 55.3 [47.1, 63.5]
Ulceration P,0.0001 P,0.001
absent 1094 (68.2%) 93.3 93.2 [91.3, 95.1] 87.3 86.2 [83.9, 88.5]
present 511 (31.8%) 83.0 75.8 [70.9, 80.7] 66.9 57.7 [52.5, 62.9]
Body site P,0.0001 P,0.001
Head and Neck 231 (12.1%) 91.3 88.7 [83.0, 94.4] 79.1 75.5 [68.5, 82.6]
Trunk 729 (38.2%) 87.0 84.3 [81.0, 87.6] 78.1 74.1 [66.3, 78.0]
Upper limb 343 (18.0%) 97.1 95.6 [92.7, 98.5] 91.3 89.2 [85.1, 93.3]
Lower limb 606 (31.7%) 89.3 88.7 [85.6, 91.8] 76.4 72.6 [68.5, 76.7]
AJCC Stage p,0.001 p,0.001
I A 90 (5.3%) 100.0 100.0 95.2 97.2 [95.2, 99.2]
I B 824 (43.2%) 96.0 96.2 [94.4, 98.0] 90.9 90.3 [89.0, 91.6]
II A 434 (22.7%) 90.6 87.0 [82.9, 91.1] 80.6 75.4 [72.9, 77.9]
II B 260 (13.6%) 83.8 78.1 [71.2, 85.0] 67.7 58.2 [54.2, 62.2]
II C 87 (4.6%) 80.5 72.6 [59.5, 83.9] 59.8 50.7 [43.0, 58.4]
III A 119 (6.2%) 73.1 72.6 [62.8, 82.4] 53.8 45.9 [40.4, 51.4]
III B 95 (5.0%) 73.7 65.6 [53.4, 77.8] 54.7 44.9 [38.7, 51.1]
Age P= 0.035 P = 0.001
,= 45-year 531 (27.8%) 92.1 92.0 [89.3, 94.7] 84.0 82.6 [78.9, 86.3]
46–60 years 529 (27.7%) 87.7 86.3 [82.8, 89.8] 78.8 76.8 [72.7, 80.9]
61–70 years 454 (23.8%) 88.1 85.0 [80.7, 89.3] 78.0 73.7 [68.8, 78.6]
.70 years 395 (20.7%) 92.7 88.0 [83.1, 92.9] 79.0 70.2 [64.1, 76.3]
Gender P= 0.068 P = 0.135
Male 1012 (53.0%) 88.8 86.2 [79.6, 93.0] 78.8 74.6 [74.5, 77.9]
Female 897(47.0%) 91.4 89.5 [87.0, 92.0] 81.6 78.0 [74.7, 81.3]
Clark-Level P,0.0001 P,0.001
Level II 12 (0.7%) 100.0 100.0 91.7 85.7 [80.7, 88.2]
Level III 209 (12.6%) 95.7 93.1 [91.0, 95.1] 89.0 88.2 [83.3, 93.1]
Level IV 1350 (81.4%) 90.8 89.1 [88.0, 90.2] 80.6 76.9 [76.8, 79.6]
Level V 88 (5.3%) 75.0 82.3 [79.1, 85.5] 60.2 55.1 [43.0, 67.2]
Histological Subtype P,0.001 P,0.001
SSM 993 (54.6%) 90.2 91.0 [89.9, 92.1] 82.6 80.6 [79.5, 81.7]
NM 437(24.0%) 86.2 82.9 [79.7, 82.3] 74.8 69.1 [66.4, 71.8]
LMM 81 (4.5%) 96.3 95.2 [69.5, 79.1] 88.9 86.2 [81.4, 91.0]
ALM 150 (8.2%) 81.3 74.3 [92.5, 97.9] 65.3 56.2 [51.2, 61.7]
Other 158 (8.7%) 95.6 93.2 [87.9, 98.5] 89.2 83.8 [76.2, 91.4]
SLNB status P,0.001 P,0.001
negative 1697 (88.9%) 92.0 90.3 [88.5, 92.1] 83.3 80.6 [78.2, 83.0]
positive 212 (11.1%) 74.5 70.9 [63.3, 78.5] 54.2 46.0 [38.0, 54.1]
SD= Standard Deviation; IQR = Inter-Quartile Range; SSM= superficial spreading melanoma, NM=nodular melanoma, LMM= lentigious malignant melanoma,
ALM=Acral lentigious melanoma; AJCC=American Joint Committee of Cancer.
doi:10.1371/journal.pone.0029791.t001
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SLNB staging had been performed for a part of these patients and
there are only few cohorts of melanoma patients with a long-term
follow-up after negative SLNB staging. The present study was
performed to evaluate survival probabilities and prognostic
factors of 1909 SLNB staged CM patients with the aim to define
groups of patients who are at higher risk for recurrences and who
should be considered for adjuvant clinical trials and undergo a
closer follow-up.
Methods
The present analysis included patients with cutaneous
melanoma (CM) diagnosed and treated by the Department of
Dermatology, University Tuebingen, Germany. Patients includ-
ed were diagnosed with incident invasive (Clark’s level of
invasion II or more) primary CM between January 1st 1996
and June 30th 2009. All patients had given their written informed
consent (Supporting Information S1), the local Ethic committee
statement had no concern (Supporting Information S2). At the
University Department of Dermatology in Tuebingen, Germany,
sentinel lymph node biopsy was introduced in January 1996 and
has been routinely performed by four dermato-surgeons over the
entire time period in all CM patients with a tumor thickness of
1.00 mm or more. SLNB was also performed in 101 patients
with smaller tumors if additional unfavorable prognostic factors
as a level of invasion IV–V, ulceration or tumor regression were
present.
Follow-up examinations were performed according to the
recommendations of the German Society of Dermatology
comprising physical examinations every three months during
years 1–5 after primary tumor diagnosis, twice yearly in years 6–
10 and, twice respectively once yearly, lymph node ultrasound and
blood tests [17]. Body site of the primary melanoma was classified
into five anatomical sites: head with scalp and neck, anterior trunk,
posterior trunk, upper and lower extremities. Histopathological
analysis of sentinel lymph nodes was based on four serial sections
performed at each of two levels. The sections from each level were
stained with H&E and immunohistochemical stains for S-100
protein, HMB-45, and Melan-A. Reports of the responsible
dermato-histopathologists were documented. SLNB containing
isolated positive tumor cells or micrometastases of #0.1 mm were
not judged as positive, in agreement with the 2002 AJCC
melanoma classification [18].
Recurrences during follow-up were distinguished as loco-
regional metastases (satellite/in-transit metastases), regional lymph
node metastases and distant metastases. Loco-regional, nodal and
distant recurrences were analyzed. Satellite metastasis was defined
as recurrence in the first melanoma field 2 cm of the edge of the
wide excision margin. In-transit metastasis was defined as
subcutaneous metastases from 2 cm to the first nodal site. Only
the first recurrence was considered for this analysis. False-negative
SNBs were defined as procedures in which the initial histopath-
ologic evaluation was negative, but the patients tumor recurred in
the same node field. Patients whose tumor recurred as satellite or
in-transit disease, followed by regional node field recurrence, were
not considered to have a false-negative SNB on the assumption
that the disease may not have been present in the regional nodes at
the time of biopsy.
Statistical analysis
Statistical analyses were performed with the statistic software
SPSS 19 (PASW, IBM SPSS, Chicago, IL, USA). Numerical
variables were described by mean value and standard deviation
(SD) if approximately normally distributed or median value and
inter-quartile range (IQR) if skewed. Proportions were presented
with 95% confidence intervals (95%-CI).
The time between primary excision of histological diagnosed
CM and the date of the last follow-up visit or the date of death was
used to calculate the follow-up time for melanoma-specific overall
survival (OS), and the date of first recurrence for the disease-free
survival (DFS), respectively. Only deaths due to CM (melanoma
specific deaths) were considered ‘‘events’’. In case that mortality
and cause of death was not directly reported, registration offices
were systematically addressed. Survival probabilities with 95%-CI
were calculated according to Kaplan-Meier and compared with
log-rank test statistics. Multivariate Cox proportional hazard
models were calculated to judge significant independent prognos-
tic factors. Forward and backward stepwise procedures of the
multivariate modeling process resulted in the same model. Results
of Cox proportional hazard modeling were described as relative
risks (hazard ratios) together with 95%-CI and p-values.
Throughout the analysis, p-values less than 0.05 were considered
as statistically significant.
Results
Selection of patients
From January 1996 to June 2009, a total of 6,028 patients with
primary cutaneous melanoma were documented by the Depart-
ment of Dermatology, Tuebingen, Germany. Patients with
advanced disease, unknown primary or melanoma in extra-
cutaneous localization (n = 660), patients without SLNB
(n= 3,330) and patients with follow-up less than 3 months
(n = 129) were excluded. The present cohort consisted of 1,909
SLNB staged patients, of these 1,697 (88.9%) with negative and
212 (11.1%) with positive SLNB. Of 1,697 SLNB negative
patients, 99 (5.8%) presented with a tumor thickness of less than
1.00 mm while there were two (0.9%) of 212 SLNB positive
patients with a tumor thickness below 1 mm. Before SLNB was
performed all patients underwent physical examinations and
lymph node ultrasound. If these examinations suggested metasta-
ses these findings were judged as macrometastases as they were
detected by clinical methods, and these patients were not included
in the present analysis.
Description of sample
The collective of 1909 SLNB staged CM patients consisted of
53.0% males and 47.0% females. The mean age at diagnosis was
55.9 years (SD616.1), the median tumor thickness was 1.80 mm
(IQR= [1.2, 2.8]). Ulceration was present in 31.8% of the primary
lesions (Table 1). The total rate of patients with recurrences was
20.2% (N=385), 35.1% of the first recurrences were satellite/
intransit metastases (N= 135), 30.9% were regional lymph node
metastases (N= 119) and 34.0% were distant metastases (N= 131).
If metastases on different sites occurred simultaneously, the
metastasis with the worst prognosis counted as first metastasis.
The rate of false negative SLN for the entire series was 13.1%.
Figure 1. Survival in sentinel node staged patients. a) Overall survival according to primary tumor thickness (p,0.001). b) Disease free survival
according to primary tumor thickness (p,0.001). c) Overall survival in patients with and without ulcerated primary tumors (p,0.001). d) Disease-free
survival in patients with and without ulcerated primary tumors (p,0.001). e) Overall survival according to AJCC stage of primary tumor (p,0.001). f)
Disease-free survival according to AJCC stage of primary tumor (p,0.001).
doi:10.1371/journal.pone.0029791.g001
Prognosis in SN Staged Melanoma Patients
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e29791
Prognosis in SN Staged Melanoma Patients
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29791
Disease related deaths occurred in 10% (n= 190; 95%CI= 8.7,
11.4). Follow up information for a period of 5-year or more was
available for 35.3% of patients, 52% of all patients were diagnosed
later than 2004 and did not yet reach a five-years follow-up at the
timepoint of the analysis. The median OS time for the whole
collective was 44 months (IQR=21, 74); while the median DFS
was 38 months (IQR=15, 68).
Prognostic factors in SLNB staged patients
Kaplan-Meier analysis of OS identified age (p= 0.035), tumor
thickness (p,0.001), body site (p,0.001), ulceration (p,0.001),
Clark level of invasion (p,0.001), histological subtype (p,0.001)
and SLNB status (p,0.001) as significant prognostic factors (see
Table 1 and Figure 1a–f). Similar results were found for DFS for
age (p= 0.001), tumor thickness (p,0.001), body site (p,0.001),
ulceration (p,0.001), Clark level of invasion (p,0.001), histolog-
ical subtype (p,0.001) and SLNB status (p,0.001) (see Table 1).
The 5-year melanoma-specific survival probabilities were 90.3%
(95%CI: 88.5; 92.1) for node-negative patients compared to 70.9%
(95%CI: 63.3, 78.5; p,0.001) for node-positive patients (see
Table 1, Figure 2a–d). The 5-year DFS for SLNB negative
patients was 80.6% (95%CI: 78.2, 83.0), vs 46.0% (95% CI: 38.0,
54.1) for SLNB positive patients.
Analyzing stages according to AJCC 2009, no significant
differences could be found for OS in stages IB-IIC compared to
IB-IIIA, the 5-year OS was 89.7% and. 88.4%, respectively,
Figures 2b–c. Stage IIC patients showed a similar 5-year OS as
stage IIIA patients (72.6%), the DFS was 50.7% and 45.9%,
respectively, see Table 1. The results of the current study are listed
and compared to those of Balch et al. [15] in Table 2.
Multivariate Cox proportional hazard analyses identified tumor
thickness, ulceration, body site, histological subtype and SLNB
status as independent significant prognostic factors for melanoma-
specific and disease-free survival, Table 3. Tumors with a thickness
of .4 mm had an increased relative risk to die of CM (5.2,
95%CI: 2.1, 12.7) compared to CM of #1.0 mm thickness
(p,0.001, Table 3). Patients with positive SLNB status were 2.3
(95%CI: 1.6, 3.1) times more likely to die from melanoma
compared to patients with negative SLNB (p,0.001). Age, gender
and Clark’s level of invasion failed to be independent significant
prognostic factors for overall and disease-free survival.
Discussion
In the last two decades, sentinel lymph node biopsy has become
a standard procedure for nodal staging in patients with primary
CM and clinically uninvolved lymph nodes. If SLNB was not part
of the management of a CM patient, this patient might not be
considered eligible for clinical trials [1]. This exclusion would not
only slow the development of more effective therapies but could
Figure 2. Overall survival in different stages of primary tumors according to AJCC 2009. a) Overall survival in stage IIIA CM patients. b)
Overall survival in stage IB- IIC CM patients. c) Overall survival in stage IB- IIIA CM patients. d) Overall survival in stage IIA-IIIA CM patients.
doi:10.1371/journal.pone.0029791.g002
Table 2. Five and 10-year melanoma-specific survival in
sentinel node-staged cutaneous melanoma patients
(n = 1909). compared to in 27,000 stage I/II and 2,587 stage
IIIA/B patients reported by Balch et al. [15,18].
Stage 5-year OS 10-Years OS
Balch Present Study Balch Present study
IB n.g* 96% n.g. 89.5%
T1b 85%
T2 80%
IIA 79–82% 87.0% n.g. 79.2%
IIB 68–71% 78.1% n.g. 64.3%
IIC 53% 72.6% n.g. 66.0%
Micrometastases 67% 70.9% n.g. 53.9%
IIIA 78% 72.6% n.g. 56.4%
IIIB 59% 65.6% n.g. 52.8%
*: n.g.: not given.
doi:10.1371/journal.pone.0029791.t002
Table 3. Prognostic factors of overall (OS) and disease-free
(DFS) survival in sentinel node-staged CM patients (n = 1909).
Results of multivariate Cox proportional hazard analysis.
OS# DFS##
Prognostic factor RR 95% CI p value RR 95% CI p value
Tumor thickness ,0.001 ,0.001
#1.0 mm 1 1
1.01–2.0 mm 1.6 0.69, 3.8 2.1 1.1, 3.8
2.01–4.0 mm 3.1 1.3, 7.2 3.8 2.0, 7.2
.4.0 mm 5.2 2.1, 12.7 5.7 3.0, 11.1
Ulceration* ,0.001 ,0.001
Absent 1 1
Present 2.1 1.5, 3.0 2.2 1.7, 2.9
Body site ,0.001 ,0.001
Upper limb 1 1
Head and Neck 3.8 1.7, 8.3 3.1 1.9, 5.0
Lower limb 2.5 1.3, 4.9 2.4 1.6, 3.6
Trunk 4.9 2.5, 9.6 2.9 1.9, 4.3
SLNB status ,0.001 ,0.001
Negative 1 1
Positive 2.3 1.6, 3.1 2.3 1.8, 3.0
Histological
subtype**
= 0.034 = 0.014
SSM 1 1
NM 1.1 0.73, 1.5 0.82 0.63, 1.1
LMM 0.72 0.20, 2.5 0.56 0.26, 1.2
ALM 2.2 1.3, 3.7 1.3 0.91, 1.9
Other 0.64 0.29, 1.4 0.54 0.32, 0.91
Gender = 0.422 = 0.639
Age = 0.166 = 0.133
Clark’s level = 0.823 = 0.747
RR =hazard ratio; 95% CI = 95% confidence interval.
*Adjusted for 304 missing values; Adjusted for 90 missing values;
#Model for melanoma-specific survival was adjusted for the confounding
effects of age and gender;
##Model for disease-free survival was adjusted for the confounding effect of
age.
doi:10.1371/journal.pone.0029791.t003
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also disadvantage patients by preventing them from receiving
adequate therapy [1].
The current study was performed in order to evaluate survival
probabilities and prognostic factors in 1909 SLNB staged CM
patients. Only few cohorts of patients with primary CM and
complete nodal staging with SLNB have been published so far
[2,12,13,19]. In most published cohorts analyzing survival, nodal
staging was either incomplete or not comparable to the present
results [3,16,19]. We found more favorable survival probabilities
compared to previously published cohorts which had incomplete
nodal staging [18]. In addition, we calculated survival probabilities
for groups of patients with different stages who were at elevated
risk for recurrences and who might be eligible for adjuvant
treatments. These stage-specific survival probabilities may be
useful for sample size calculations for future melanoma trials.
In the 2009 AJCC staging classification Balch and co-workers
investigated 27000 CM patients in stage I/II and 2313 in stage III
with complete follow-up data in the AJCC melanoma staging
database [15,18]. For the 27000 stage I/II patients with primary
CM, tumor thickness, mitotic rate and ulceration were the most
dominant prognostic factors.
Comparing the results of Balch et al. [18] to those of the present
study, our patients showed an advanced 5-/10 year survival-
probability, see Table 2. These discrepancies and improved
survival for stage IB-IIC in our analysis may be caused by the fact
that the data of 27000 patients in stages I/II published by Balch et
al [18], may also include patients who had not undergone SLNB
and were not truly negative for micro-metastases [18]. In
particular, in stages IIB-IIC the discrepancies between our results
and Balch’s are greatest (Table 2). However, in these stages the
27000 patients were at the highest risk of unrecognized micro-
metastases [18].
Several studies on prognostic factors in primary melanoma
patients with negative SLNB have been published in the last years
[3,18,19] confirming the impact of tumor thickness and ulceration.
Yee et al reported a similar 5-year OS of 90% for all SLNB
negative patients, ranging from 78% to 94% for patients with or
without ulceration which is nearly identical to our results
(Table 1a,b) [3]. In the present study SLNB containing isolated
positive tumor cells or micrometastases of #0.1 mm were not
judged as positive. This is in accordance to a recent publication
from Eggermont’s group [20]. In this study of 1,080 patients from
van der Ploeg et al the 5 years OS of 91% in patients with
micrometastases ,0.1 mm in diameter was shown to be similar to
those of SLNB negative patients. These results are in accordance
to the five-years OS (90.6%) in SLNB negative patients in the
current analysis [20]. Patients with micrometastases from 0.1 to
1.0 mm showed a similar 5-years OS of 74% [20] than stage IIIA
patients in our study (72.6%).
Ulceration remains the second important prognostic factor
associated with unfavorable survival [7,15,16,18]. Survival rates of
patients with an ulcerated CM were previously found similar to
those of patients with a non-ulcerated CM of the next higher
tumor thickness category [15,18]. This is in concordance to our
results, where ulceration proofed to be an independent significant
prognostic factor in primary CM and in the total collective of
SLNB staged patients (Tables 1, 3 and Figure 1c,d).
In our collective of positive and negative SLNB staged patients,
SLNB status, tumor thickness, ulceration, histological subtype and
body site were identified as independent significant prognostic
factors for DFS and OS during multivariate analyses. In order to
define subgroups for clinical trials, histological subtype and body
site may provide additional prognostic information. The SLN
status was shown to be a highly significant prognostic factor with a
5-year OS of about 90.3% in negative SLNB and 70.9% in
positive SLNB. The impact of the SLN status, tumor thickness and
ulceration on DFS and OS has been confirmed by various
publications [3,4,12,13]. In addition, histological subtype was
reported to be a further significant independent prognostic factor
[21,22] for OS and DFS. Studies in SLNB negative patients did
not show this effect [3]. In patients with stage III disease body site
was shown to be a further prognostic factor [15].
One limitation of the present study is the missing information
for mitotic rate. Until January 2010, the mitotic rate of primary
melanoma was not determined in Germany. However we do not
expect that this limitation would change our results markedly. A
positive mitotic rate upstages patients with tumor thickness less
than 1.0 mm which would then be classified as stage IB instead of
IA. In our collective the number of patients with tumor thickness
less than 1 mm was small (5.3%), and hence a marked change of
the OS and DFS is unlikely.
Conclusion
The current study was performed to evaluate the survival
probabilities and prognostic factors of 1909 SLNB staged CM
patients. Five year survival rates for different subgroups eligible for
adjuvant trials were found to be quite favourable (five years
Overall Survival rates of 89.7% in stages IB – IIC, 88.4% in stages
IB – IIIA, 81.1% in stages IIA – IIIA, 68.8% in stages IIIA/B).
The prognosis for primary CM patients without micro-metastases
in SLNB seems to be more favorable than previously reported. It is
suggested that this is mainly due to the exclusion of sentinel-node
positive patients from stages I–II. It is necessary to adapt sample
size calculations for survival probabilities classified by the presently
valid AJCC staging system.
Supporting Information
Supporting Information S1 Informed consent.
(PDF)
Supporting Information S2 Statement of the local Ethic
Committee.
(PDF)
Author Contributions
Conceived and designed the experiments: UL CG. Performed the
experiments: OE UL PB CG. Analyzed the data: OE UL PB CG.
Contributed reagents/materials/analysis tools: TE FM BW GM HB UL.
Wrote the paper: OE UL PB CG.
References
1. Balch CM, Morton DL, Gershenwald JE, McMasters KM, Nieweg OE, et al.
(2009) Sentinel node biopsy and standard of care for melanoma. J Am Acad
Dermatol 60: 872–5.
2. Phan GQ, Messina JL, Sondak VK, Zager JS (2009) Sentinel lymph node biopsy
for melanoma: indications and rationale. Cancer Control 16: 234–9.
3. Yee VS, Thompson JF, McKinnon JG, Scolyer RA, Li LX, et al. (2005)
Outcome in 846 cutaneous melanoma patients from a single center after a
negative sentinel node biopsy. Ann Surg Oncol 12: 429–39.
4. Essner R, Conforti A, Kelley MC, Wanek L, Stern S, et al. (1999) Efficacy of
lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph
node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg
Oncol JID - 9420840 6: 442–9.
5. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, et al. (2006)
Sentinel-node biopsy or nodal observation inmelanoma.NEngl JMed 355: 1307–17.
6. Morton DL, Cochran AJ, Thompson JF (2008) The rationale for sentinel-node
biopsy in primary melanoma. Nat Clin Pract Oncol 5: 510–1.
Prognosis in SN Staged Melanoma Patients
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29791
7. McMasters KM, Wong SL, Edwards MJ, Ross MI, Chao C, et al. (2001) Factors
that predict the presence of sentinel lymph node metastasis in patients with
melanoma. Surgery 130: 151–6.
8. Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, et al. (2005)
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in
MSLT-I, an international multicenter trial. Ann Surg 242: 302–11.
9. Cascinelli N, Belli F, Santinami M, Fait V, Testori A, et al. (2000) Sentinel
lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program
experience. Ann Surg Oncol 7: 469–74.
10. Chao C, Wong SL, Ross MI, Reintgen DS, Noyes RD, et al. (2002) Patterns of
early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 184:
520–4.
11. Gadd MA, Cosimi AB, Yu J, Duncan LM, Yu L, et al. (1999) Outcome of
patients with melanoma and histologically negative sentinel lymph nodes. Arch
Surg 134: 381–7.
12. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, et al. (1998)
Patterns of recurrence following a negative sentinel lymph node biopsy in 243
patients with stage I or II melanoma. J Clin Oncol JID - 8309333 16: 2253–60.
13. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W (2003) Sentinel
lymph node biopsy in melanoma patients with clinically negative regional lymph
nodes–one institution’s experience. Melanoma Res 13: 35–43.
14. Wagner JD, Gordon MS, Chuang TY, Coleman JJ, III (2000) Current therapy
of cutaneous melanoma. Plast Reconstr Surg 105: 1774–99.
15. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, et al. (2010)
Multivariate analysis of prognostic factors among 2,313 patients with stage III
melanoma: comparison of nodal micrometastases versus macrometastases. J Clin
Oncol 28: 2452–9.
16. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, et al. (2001)
Prognostic factors analysis of 17,600 melanoma patients: validation of the
American Joint Committee on Cancer melanoma staging system. J Clin Oncol
JID - 8309333 19: 3622–34.
17. Garbe C (2003) A rational approach to the follow-up of melanoma patients.
Recent Results Cancer Res JID - 0044671 160: 205–15.
18. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009)
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol
27: 6199–206.
19. Zogakis TG, Essner R, Wang HJ, Turner RR, Takasumi YT, et al. (2005)
Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch
Surg 140: 865–71.
20. van der Ploeg AP, van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, et al.
(2011) Prognosis in patients with sentinel node-positive melanoma is accurately
defined by the combined Rotterdam tumor load and Dewar topography criteria.
J Clin Oncol 29: 2206–14.
21. Kunte C, Geimer T, Baumert J, Konz B, Volkenandt M, et al. (2010) Prognostic
factors associated with sentinel lymph node positivity and effect of sentinel status
on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma
Res 20: 330–7.
22. Mandala M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, et al. (2009)
Clinical and histopathological risk factors to predict sentinel lymph node
positivity, disease-free and overall survival in clinical stages I–II AJCC skin
melanoma: outcome analysis from a single-institution prospectively collected
database. Eur J Cancer 45: 2537–45.
Prognosis in SN Staged Melanoma Patients
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29791
